Hollie Franklin, Author at Drugs in Context

Acute bacterial sinusitis in children: an updated review

Alexander KC Leung MBBS, FRCPC, FRCP (UK and Irel), FRCPCH, FAAP, Kam Lun Hon MD, FAAP, FCCM, Winnie CW Chu MD, FRCR

Article Type

Review

Published

23 Nov 2020

This article is an updated narrative review on the evaluation, diagnosis, and management of acute bacterial sinusitis.

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type

Review

Published

16 Nov 2020

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Namrata Singhania MD, Saurabh Bansal MD, Shreya Mohandas, Divya P Nimmatoori MD, Abutaleb A Ejaz MD, Girish Singhania MD

Article Type

Review

Published

11 Nov 2020

This narrative review summarizes the role of renin–angiotensin–aldosterone system inhibitors in acute and chronic heart failure and chronic kidney disease.

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD

Article Type

Original Research

Published

19 Oct 2020

This post hoc analysis of SELECT-COMPARE reports, for the first time, the efficacy and safety of upadacitinib 15 mg in combination with methotrexate
(MTX) in patients from the Central and Eastern European region with MTX inadequate response rheumatoid arthritis compared with placebo or adalimumab with MTX up to 48 weeks of follow-up.

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Diego Conde-Royo MD, Luis Miguel Juárez-Salcedo MD, Samir Dalia MD

Article Type

Review

Published

14 Oct 2020

This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.